Comments
Loading...

Galmed Pharmaceuticals Analyst Ratings

GLMDNASDAQ
Logo brought to you by Benzinga Data
$1.37
0.097.03%
At close: -
$1.35
-0.02-1.46%
After Hours: 5:36 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$4.00
Lowest Price Target1
$1.00
Consensus Price Target1
$2.50

Galmed Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:GLMD | Benzinga

Galmed Pharmaceuticals Ltd has a consensus price target of $2.5 based on the ratings of 3 analysts. The high is $4 issued by Maxim Group on July 24, 2023. The low is $1 issued by Canaccord Genuity on August 8, 2022. The 2 most-recent analyst ratings were released by Maxim Group and Canaccord Genuity on July 24, 2023 and August 8, 2022, respectively. With an average price target of $2.5 between Maxim Group and Canaccord Genuity, there's an implied 85.19% upside for Galmed Pharmaceuticals Ltd from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Maxim Group
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Galmed Pharmaceuticals

Buy NowGet Alert
04/04/2025Buy NowMaxim Group
Naz Rahman28%
DowngradeBuy → HoldGet Alert
07/24/2023Buy Now196.3%Maxim Group
Jason McCarthy42%
→ $4UpgradeHold → BuyGet Alert
08/08/2022Buy NowMaxim Group
Jason McCarthy42%
DowngradeBuy → HoldGet Alert
08/08/2022Buy Now-25.93%Canaccord Genuity
Edward Nash65%
$5 → $1DowngradeBuy → HoldGet Alert

FAQ

Q

What is the target price for Galmed Pharmaceuticals (GLMD) stock?

A

The latest price target for Galmed Pharmaceuticals (NASDAQ:GLMD) was reported by Maxim Group on April 4, 2025. The analyst firm set a price target for $0.00 expecting GLMD to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Galmed Pharmaceuticals (GLMD)?

A

The latest analyst rating for Galmed Pharmaceuticals (NASDAQ:GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals downgraded their hold rating.

Q

When was the last upgrade for Galmed Pharmaceuticals (GLMD)?

A

The last upgrade for Galmed Pharmaceuticals Ltd happened on July 24, 2023 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Galmed Pharmaceuticals Ltd.

Q

When was the last downgrade for Galmed Pharmaceuticals (GLMD)?

A

The last downgrade for Galmed Pharmaceuticals Ltd happened on April 4, 2025 when Maxim Group changed their price target from N/A to N/A for Galmed Pharmaceuticals Ltd.

Q

When is the next analyst rating going to be posted or updated for Galmed Pharmaceuticals (GLMD)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on April 4, 2025 so you should expect the next rating to be made available sometime around April 4, 2026.

Q

Is the Analyst Rating Galmed Pharmaceuticals (GLMD) correct?

A

While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a downgraded with a price target of $0.00 to $0.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $1.35, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.